Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of SAL0133 in Healthy Chinese Adults
NCT07030504Phase 1Active, not recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jan 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAL0133 in coronavirus disease 2019 (COVID-19), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoints: The rate of AE, The rate of SAE and 1 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
SAL0133
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07030504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030504.